EPO and chronic kidney disease: Furthermore, our group has previously reported lower sFas renal clearance in patients with increased serum levels sFas, which was associated with anemia, hyporesponsiveness to EPO, and increased need for ESA in patients with CKD during six years of follow-up, in addition to inhibiting erythroid cell growth in vitro [9, 18, 21].